文献速递冠心病心力衰竭与心肌病血脂与心血管预防

非编码RNA在心血管疾病中的诊断与治疗前景

Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.
PubMed 文献 · Eur Heart J · 2018-01-01

综述指出非编码基因组在心血管疾病中起关键调控作用,ncRNAs可作为改善诊断和预后评估的候选标志物,并正成为新型治疗靶点与工具;RNAi药物靶向肝脏PCSK9合成可显著降低LDL胆固醇,靶向肝脏TTR合成用于治疗心脏TTR淀粉样变性。

要点

  • 约99%的人类基因组不编码蛋白质但具有转录活性,产生广泛谱系的非编码RNA。
  • ncRNAs是心血管危险因素和细胞功能的关键新型调节因子,可作为诊断和预后评估的候选。
  • RNAi药物靶向肝脏PCSK9合成可高度显著降低LDL胆固醇,靶向肝脏TTR合成用于治疗心脏TTR淀粉样变性。

核心结论

  • 非编码RNA是心血管疾病诊断与预后评估的重要候选,并正成为新型治疗靶点与治疗工具。

研究设计与样本

  • 综述,涵盖动脉粥样硬化/冠状动脉疾病、心肌梗死后重构和心力衰竭领域ncRNAs诊断与治疗应用的最新进展。

主要发现

  • 约99%的人类基因组不编码蛋白质但具有转录活性,产生广泛谱系的非编码RNA。
  • ncRNAs被确定为心血管危险因素和细胞功能的关键新型调节因子。
  • ncRNAs作为新型治疗靶点,部分正进入临床试验评估。
  • 以内源性ncRNAs为蓝图开发了新型治疗工具,RNAi药物利用内源性短干扰RNA通路高效沉默蛋白表达。

关键数值与推荐

  • RNAi药物靶向肝脏PCSK9合成导致LDL胆固醇高度显著降低。
  • RNAi药物靶向肝脏TTR合成用于治疗心脏TTR淀粉样变性。

临床怎么用

  • ncRNAs可作为改善心血管疾病诊断和预后评估的候选标志物。
  • ncRNAs相关治疗靶点部分正进入临床试验评估。
  • RNAi药物是高效沉默蛋白表达的工具,已有靶向PCSK9和TTR的先导临床研究。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent research has demonstrated that the non-coding genome plays a key role in genetic programming and gene regulation during development as well as in health and cardiovascular disease. About 99% of the human genome do not encode proteins, but are transcriptionally active representing a broad spectrum of non-coding RNAs (ncRNAs) with important regulatory and structural functions. Non-coding RNAs have been identified as critical novel regulators of cardiovascular risk factors and cell functions and are thus important candidates to improve diagnostics and prognosis assessment. Beyond this, ncRNAs are rapidly emgerging as fundamentally novel therapeutics. On a first level, ncRNAs provide novel therapeutic targets some of which are entering assessment in clinical trials. On a second level, new therapeutic tools were developed from endogenous ncRNAs serving as blueprints. Particularly advanced is the development of RNA interference (RNAi) drugs which use recently discovered pathways of endogenous short interfering RNAs and are becoming versatile tools for efficient silencing of protein expression. Pioneering clinical studies include RNAi drugs targeting liver synthesis of PCSK9 resulting in highly significant lowering of LDL cholesterol or targeting liver transthyretin (TTR) synthesis for treatment of cardiac TTR amyloidosis. Further novel drugs mimicking actions of endogenous ncRNAs may arise from exploitation of molecular interactions not accessible to conventional pharmacology. We provide an update on recent developments and perspectives for diagnostic and therapeutic use of ncRNAs in cardiovascular diseases, including atherosclerosis/coronary disease, post-myocardial infarction remodelling, and heart failure.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Poller W, Dimmeler S, Heymans S, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. 2018. PMID: 28430919. doi:10.1093/eurheartj/ehx165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。